Table 1.
Baseline characteristics of the 60 non-cirrhotic patients with chronic HCV
| Characteristica | A | B | C | D |
|---|---|---|---|---|
| All | Normal BMD | Low BMD | p value | |
| n = 60 | n = 35 (58 %) | n = 25 (42 %) | ||
| Age (years) | 53.3 (5.7) | 52.6 (5.6) | 54.2 (5.8) | 0.27 |
| Female | 32 (53 %) | 16 (46 %) | 16 (64 %) | 0.16 |
| Postmenopauseb | 24 (75 %) | 8 (50 %) | 16 (67 %) | <0.01 |
| Race/ethnicity | 0.32 | |||
| Non-Hispanic White | 32 (53 %) | 15 (43 %) | 17 (68 %) | |
| African-American | 15 (25 %) | 11 (31 %) | 4 (16 %) | |
| Hispanic White | 11 (18 %) | 7 (20 %) | 4 (16 %) | |
| Other | 2 (3 %) | 2 (6 %) | 0 (0 %) | |
| Type II diabetes | 17 (28 %) | 9 (26 %) | 8 (32 %) | 0.59 |
| Tobacco use ever | 32 (53 %) | 21 (60 %) | 11 (44 %) | 0.22 |
| Current tobacco use | 15 (25 %) | 7 (20 %) | 8 (32 %) | 0.29 |
| Heavy alcohol use ever | 21 (35 %) | 14 (40 %) | 7 (28 %) | 0.34 |
| Family history of osteoporosis | 12 (20 %) | 6 (17 %) | 6 (24 %) | 0.51 |
| Body mass index | 28.4 (6.5) | 29.9 (7.0) | 26.2 (5.1) | 0.03 |
| Total bilirubin (mg/dL) | 0.7 (0.3) | 0.7 (0.4) | 0.7 (0.3) | 0.52 |
| Creatinine (mg/dL) | 0.8 (0.2) | 0.9 (0.1) | 0.8 (0.2) | 0.08 |
| eGFR (mL/min) | 93.9 (14.4) | 93.3 (13.9) | 94.8 (13.9) | 0.69 |
| Albumin (g/dL) | 4 (0.3) | 3.9 (0.4) | 4.0 (0.3) | 0.45 |
| Platelet count (109/L) | 206 (54) | 204 (62) | 208 (62) | 0.77 |
| Had a liver biopsy within 1 year of enrollment | 32 (53 %) | 17 (49 %) | 15 (60 %) | 0.38 |
| Fibrosis stage ≥2 | 14 (33 %) | 8 (35 %) | 6 (30 %) | 0.74 |
| Log HCV RNA (IU/mL) | 6.0 (0.6) | 6.1 (0.7) | 6.0 (0.4) | 0.39 |
| Prior HCV treatment | 14 (23 %) | 8 (23 %) | 6 (24 %) | 0.92 |
| Medication use | ||||
| Calcium | 10 (17 %) | 3 (9 %) | 7 (28 %) | 0.05 |
| Vitamin D | 15 (25 %) | 10 (29 %) | 5 (20 %) | 0.45 |
| Proton-pump inhibitor | 7 (12 %) | 5 (14 %) | 2 (8 %) | 0.46 |
| Estrogen (women only) | 2 (7 %) | 1 (3 %) | 1 (4 %) | 0.81 |
a
Mean (standard deviation) or n (%)
b
n (% of the 32 women)